In the third of this 3-part CEC Oncology BriefCase series, expert faculty and a patient advocate delve into interprofessional strategies for preventing and mitigating adverse events while collaboratively promoting QoL for patients being treated for HER2-negative MBC.
In the second of this 3-part CEC Oncology BriefCase series, expert faculty review emerging data on ADC therapy for HER2-negative MBC, describe therapy selection and treatment sequencing rationale, and hear from a patient advocate about patient concerns regarding this new therapy option.
In the first of this 3-part CEC Oncology BriefCase series, expert faculty introduce clinicians to ADC therapy for HER2-negative MBC and hear from a patient advocate about patient concerns regarding this new therapy option.
